94 related articles for article (PubMed ID: 32083800)
1. Upregulation of long noncoding RNA Lnc-IRF2-3 and Lnc-ZNF667-AS1 is associated with poor survival in B-chronic lymphocytic leukemia.
El-Khazragy N; Esmaiel MA; Mohamed MM; Hassan NS
Int J Lab Hematol; 2020 Jun; 42(3):284-291. PubMed ID: 32083800
[TBL] [Abstract][Full Text] [Related]
2. Analysis of Long Noncoding RNA ZNF667-AS1 as a Potential Biomarker for Diagnosis and Prognosis of Glioma Patients.
Yuan Q; Gao C; Lai XD; Chen LY; Lai TB
Dis Markers; 2020; 2020():8895968. PubMed ID: 33282010
[TBL] [Abstract][Full Text] [Related]
3. Long noncoding RNA ZNF667-AS1 reduces tumor invasion and metastasis in cervical cancer by counteracting microRNA-93-3p-dependent PEG3 downregulation.
Li YJ; Yang Z; Wang YY; Wang Y
Mol Oncol; 2019 Nov; 13(11):2375-2392. PubMed ID: 31420931
[TBL] [Abstract][Full Text] [Related]
4. Lnc-SOX6-1 upregulation correlates with poor risk stratification and worse treatment outcomes, and promotes cell proliferation while inhibits apoptosis in pediatric acute myeloid leukemia.
Guan X; Wen X; Xiao J; An X; Yu J; Guo Y
Int J Lab Hematol; 2019 Apr; 41(2):234-241. PubMed ID: 30624855
[TBL] [Abstract][Full Text] [Related]
5. ZNF667-AS1, a positively regulating MEGF10, inhibits the progression of uveal melanoma by modulating cellular aggressiveness.
Yang H; Cai MY; Rong H; Ma LR; Xu YL
J Biochem Mol Toxicol; 2021 May; 35(5):e22732. PubMed ID: 33512044
[TBL] [Abstract][Full Text] [Related]
6. Independent prognostic Factor of low-expressed LncRNA ZNF667-AS1 for cervical cancer and inhibitory function on the proliferation of cervical cancer.
Zhao LP; Li RH; Han DM; Zhang XQ; Nian GX; Wu MX; Feng Y; Zhang L; Sun ZG
Eur Rev Med Pharmacol Sci; 2017 Dec; 21(23):5353-5360. PubMed ID: 29243775
[TBL] [Abstract][Full Text] [Related]
7. lncRNA profiling in early-stage chronic lymphocytic leukemia identifies transcriptional fingerprints with relevance in clinical outcome.
Ronchetti D; Manzoni M; Agnelli L; Vinci C; Fabris S; Cutrona G; Matis S; Colombo M; Galletti S; Taiana E; Recchia AG; Bossio S; Gentile M; Musolino C; Di Raimondo F; Grilli A; Bicciato S; Cortelezzi A; Tassone P; Morabito F; Ferrarini M; Neri A
Blood Cancer J; 2016 Sep; 6(9):e468. PubMed ID: 27611921
[TBL] [Abstract][Full Text] [Related]
8. Aberrant methylation and downregulation of ZNF667-AS1 and ZNF667 promote the malignant progression of laryngeal squamous cell carcinoma.
Meng W; Cui W; Zhao L; Chi W; Cao H; Wang B
J Biomed Sci; 2019 Jan; 26(1):13. PubMed ID: 30684967
[TBL] [Abstract][Full Text] [Related]
9. Prognostic and clinicopathologic significance of long non-coding RNA opa-interacting protein 5-antisense RNA 1 in multiple human cancers.
Ren X; He J; Qi L; Li S; Zhang C; Duan Z; Wang W; Tu C; Li Z
Artif Cells Nanomed Biotechnol; 2020 Dec; 48(1):353-361. PubMed ID: 31899963
[No Abstract] [Full Text] [Related]
10. FCRL2 mRNA expression is inversely associated with clinical progression in chronic lymphocytic leukemia.
Nückel H; Collins CH; Frey UH; Sellmann L; Dürig J; Siffert W; Dührsen U
Eur J Haematol; 2009 Dec; 83(6):541-9. PubMed ID: 19682311
[TBL] [Abstract][Full Text] [Related]
11. LncRNA
Di Fiore R; Suleiman S; Drago-Ferrante R; Felix A; O'Toole SA; O'Leary JJ; Ward MP; Beirne J; Yordanov A; Vasileva-Slaveva M; Subbannayya Y; Pentimalli F; Giordano A; Calleja-Agius J
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360598
[TBL] [Abstract][Full Text] [Related]
12. LncRNA ZNF667-AS1 inhibits inflammatory response and promotes recovery of spinal cord injury via suppressing JAK-STAT pathway.
Li JW; Kuang Y; Chen L; Wang JF
Eur Rev Med Pharmacol Sci; 2018 Nov; 22(22):7614-7620. PubMed ID: 30536300
[TBL] [Abstract][Full Text] [Related]
13. In chronic lymphocytic leukaemia with complex karyotype, major structural abnormalities identify a subset of patients with inferior outcome and distinct biological characteristics.
Rigolin GM; Saccenti E; Guardalben E; Cavallari M; Formigaro L; Zagatti B; Visentin A; Mauro FR; Lista E; Bassi C; Lupini L; Quaglia FM; Urso A; Bardi MA; Bonaldi L; Volta E; Tammiso E; Ilari C; Cafforio L; Melandri A; Cavazzini F; Negrini M; Semenzato G; Trentin L; Foà R; Cuneo A
Br J Haematol; 2018 Apr; 181(2):229-233. PubMed ID: 29611195
[TBL] [Abstract][Full Text] [Related]
14. The long noncoding RNA, treRNA, decreases DNA damage and is associated with poor response to chemotherapy in chronic lymphocytic leukemia.
Miller CR; Ruppert AS; Fobare S; Chen TL; Liu C; Lehman A; Blachly JS; Zhang X; Lucas DM; Grever MR; Tallman MS; Flinn IW; Rassenti LZ; Kipps TJ; Sampath D; Coombes KR; Hertlein EK
Oncotarget; 2017 Apr; 8(16):25942-25954. PubMed ID: 28412730
[TBL] [Abstract][Full Text] [Related]
15. Identification of a novel, internal tRNA-derived RNA fragment as a new prognostic and screening biomarker in chronic lymphocytic leukemia, using an innovative quantitative real-time PCR assay.
Katsaraki K; Artemaki PI; Papageorgiou SG; Pappa V; Scorilas A; Kontos CK
Leuk Res; 2019 Dec; 87():106234. PubMed ID: 31669784
[TBL] [Abstract][Full Text] [Related]
16. Correlation of Long Noncoding RNA SEMA6A-AS1 Expression with Clinical Outcome in HBV-Related Hepatocellular Carcinoma.
Yu S; Li N; Wang J; Fu Y; Huang Y; Yi P; Chen R; Tang D; Hu X; Fan X
Clin Ther; 2020 Mar; 42(3):439-447. PubMed ID: 32070484
[TBL] [Abstract][Full Text] [Related]
17. The prognostic role of CXCR3 expression by chronic lymphocytic leukemia B cells.
Ocaña E; Delgado-Pérez L; Campos-Caro A; Muñóz J; Paz A; Franco R; Brieva JA
Haematologica; 2007 Mar; 92(3):349-56. PubMed ID: 17339184
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of MAPT-AS1 is associated with better patient survival in breast cancer.
Wang D; Li J; Cai F; Xu Z; Li L; Zhu H; Liu W; Xu Q; Cao J; Sun J; Tang J
Biochem Cell Biol; 2019 Apr; 97(2):158-164. PubMed ID: 30074401
[TBL] [Abstract][Full Text] [Related]
19. Investigation of the Clinical Significance and Prognostic Value of the lncRNA
Nie Y; Jiao Y; Li Y; Li W
Biomed Res Int; 2019; 2019():4602371. PubMed ID: 31886217
[TBL] [Abstract][Full Text] [Related]
20. mRNA overexpression of kallikrein-related peptidase 14 (KLK14) is an independent predictor of poor overall survival in chronic lymphocytic leukemia patients.
Kontos CK; Adamopoulos PG; Papageorgiou SG; Pappa V; Scorilas A
Clin Chem Lab Med; 2016 Feb; 54(2):315-24. PubMed ID: 26351937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
